Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 2Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Papillomavirus Infections 1Cancer Survivor 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Vaccines, Synthetic × Clear all
NCT01492582 2021-10-27

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

University of Alabama at Birmingham

Phase 2 Completed
1,499 enrolled 11 charts

Cancer Survivor

NCT00411749 2017-04-21

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Merck Sharp & Dohme LLC

Phase 2 Completed
107 enrolled 12 charts

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡